Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)
|
HLA-G positive
|
Actemra IV (tocilizumab) • RG6353